Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

- clinical dose escalation data for sns-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts -
SNSE Ratings Summary
SNSE Quant Ranking